文献速递骨软组织肉瘤与黑色素瘤

博替利单抗(Fc增强型抗细胞毒性T淋巴细胞相关蛋白4抗体)联合巴替利单抗(抗PD-1抗体)治疗复发/难治性转移性肉瘤患者

Botensilimab (Fc-enhanced anti-cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti-PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas.
PubMed 文献 · J Clin Oncol · 2025-01-27

这项I期研究评估博替利单抗联合巴替利单抗在晚期肉瘤中的安全性与疗效,64例患者接受治疗,最常见治疗相关不良事件为腹泻/结肠炎(35.9%),可评估患者客观缓解率为19.2%,中位无进展生存期4.4个月,作者认为该联合方案在经重度治疗的肉瘤患者中显示出有前景的疗效与安全性,值得进一步研究。

要点

  • 64例肉瘤患者接受博替利单抗联合巴替利单抗治疗,最常见治疗相关不良事件为腹泻/结肠炎,发生率35.9%。
  • 可评估患者客观缓解率为19.2%(95%CI 9.6至32.5),血管肉瘤可评估患者为27.8%(95%CI 9.7至53.5)。
  • 可评估患者中位无进展生存期4.4个月(95%CI 2.8至6.1),中位缓解持续时间21.7个月(95%CI 1.9至未达到)。

核心结论

  • 博替利单抗联合巴替利单抗在经重度治疗的肉瘤患者中显示出有前景的疗效与安全性,作者认为该活性值得进一步研究。

研究设计与样本

  • 这项I期研究纳入64例晚期肉瘤患者,全部可评估安全性,52例可评估疗效。
  • 博替利单抗按1 mg/kg或2 mg/kg每6周一次静脉给药,联合巴替利单抗按3 mg/kg每2周一次静脉给药,最长2年。
  • 主要终点为剂量递增期剂量限制性毒性,次要终点包括客观缓解率、缓解持续时间、疾病控制率和无进展生存期(按RECIST 1.1)。

主要发现

  • 最常见治疗相关不良事件为腹泻/结肠炎,发生于35.9%的患者,其中3级占6.3%,未报告4级或5级治疗相关不良事件。
  • 全部可评估患者客观缓解率为19.2%(95%CI 9.6至32.5)。
  • 血管肉瘤可评估患者(n=18)客观缓解率为27.8%(95%CI 9.7至53.5),其中内脏亚型为33.3%,皮肤亚型为22.2%。
  • 可评估患者中位无进展生存期为4.4个月(95%CI 2.8至6.1),6个月无进展生存率为36%(95%CI 22至50)。
  • 可评估患者中位缓解持续时间为21.7个月(95%CI 1.9至未达到)。

局限性

  • 原文报告该研究为I期研究,结论指出该联合方案的活性值得进一步研究(warrants further investigation)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Outcomes for patients with advanced sarcomas are poor and there is a high unmet need to develop novel therapies. The purpose of this phase I study was to define the safety and efficacy of botensilimab (BOT), an Fc-enhanced anti-cytotoxic lymphocyte-association protein-4 antibody, plus balstilimab (BAL), an anti-PD-1 antibody, in advanced sarcomas. METHODS: BOT was administered intravenously (IV) at 1 mg/kg or 2 mg/kg once every 6 weeks in combination with BAL IV at 3 mg/kg once every 2 weeks for up to 2 years. The primary end point was to determine dose-limiting toxicities during the dose-escalation period. Secondary end points include objective response rate (ORR), duration of response (DOR), disease control rate, and progression-free survival (PFS) by RECIST 1.1. Exploratory end points include assessing patient biomarkers including tumor mutational burden, cytokines, and PD-L1 expression. RESULTS: Overall, 64 patients with sarcoma were treated; all were evaluable for safety and 52 for efficacy. The most common treatment-related adverse event (TRAE) was diarrhea/colitis occurring in 35.9% of patients, with grade 3 in 6.3% of patients. No grade 4 or 5 TRAEs were reported. For all evaluable patients, ORR was 19.2% (95% CI, 9.6 to 32.5), and 27.8% (95% CI, 9.7 to 53.5) for evaluable patients with angiosarcoma (n = 18); 33.3% in visceral and 22.2% in cutaneous subtypes. Median PFS for evaluable patients was 4.4 months (95% CI, 2.8 to 6.1), with a 6-month PFS rate of 36% (95% CI, 22 to 50) and a median DOR of 21.7 months (95% CI, 1.9 to not reached). CONCLUSION: The combination of BOT/BAL demonstrated promising efficacy and safety in a large cohort of heavily pretreated sarcoma patients. This encouraging activity warrants further investigation (ClinicalTrials.gov identifier: NCT03860272).

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Wilky BA, Schwartz GK, Gordon MS, et al. Botensilimab (Fc-enhanced anti-cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti-PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas. J Clin Oncol. 2025. PMID: 39869830. doi:10.1200/JCO-24-02524

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。